13.2 Peripheral Arterial Disease & Ischemic Extremity Ulcerations

13.2 Peripheral Arterial Disease & Ischemic Extremity Ulcerations

Core Clinical Principle: Peripheral Arterial Disease (PAD) of the lower extremities is the vascular manifestation of systemic atherosclerosis. When arterial inflow falls below the baseline metabolic threshold required to maintain resting cellular viability, the limb enters the critical phase of Chronic Limb-Threatening Ischemia (CLTI). In this state, trivial mechanical trauma or pressure initiates an ischemic cascade culminating in sharply demarcated, non-healing arterial ulceration and progressive gangrene.

Lower extremity PAD affects over 230 million people worldwide and is an independent predictor of major adverse cardiovascular events (MACE), including myocardial infarction and stroke. Within the specialized wound care setting, distinguishing between stable exertional claudication and decompensated CLTI is vital. A missed or delayed diagnosis of critical ischemia carries an imminent risk of major limb amputation and severe patient mortality.

---

Pathobiology of Atherosclerosis Obliterans in the Lower Extremity

Atherosclerosis obliterans is a chronic, lipid-driven, maladaptive inflammatory disease of large- and medium-sized muscular arteries. Its cellular evolution spans decades:

+-------------------------------------------------------------------------------------------------+
|                     CELLULAR CASCADES OF ATHEROSCLEROSIS OBLITERANS                             |
+-------------------------------------------------------------------------------------------------+
| 1. ENDOTHELIAL INJURY & DYSFUNCTION                                                             |
|    • Hemodynamic shear stress, smoking toxins, hypertension, oxidized LDL, and hyperglycemia   |
|    • Upregulation of VCAM-1, ICAM-1, and E-selectin; downregulation of endothelial NO synthase   |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 2. MONOCYTE RECRUITMENT & FOAM CELL ACCUMULATION                                                |
|    • Monocytes extravasate into subendothelial intima -> Differentiate into macrophages         |
|    • Scavenger receptors (SR-A, CD36) engulf oxidized LDL particles unrestrained                |
|    • Transformation into lipid-laden FOAM CELLS -> Aggregation forms FATTY STREAKS              |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 3. FIBROUS PLAQUE FORMATION & INTIMAL EXPANSION                                                |
|    • Macrophages secrete PDGF, TGF-β, and FGF -> Stimulate vascular smooth muscle migration    |
|    • Vascular smooth muscle cells (VSMCs) migrate from media into intima, synthesizing collagen |
|    • Formation of a dense FIBROUS CAP overlying a necrotic lipid core (Atheroma)                |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| 4. CALCIFICATION, PLAQUE RUPTURE & LUMINAL OCCLUSION                                            |
|    • Macrophage-derived MMPs degrade fibrous cap; dystrophic calcification stiffens arterial wall|
|    • Endothelial denudation or cap rupture triggers platelet adherence and fibrin thrombus      |
|    • Fixed luminal stenosis (>70% cross-sectional area loss) impairs distal pressure & perfusion|
+-------------------------------------------------------------------------------------------------+

Anatomic Patterns of Arterial Occlusive Disease

Lower extremity atherosclerosis typically distributes across three distinct anatomical levels:

1. Aortoiliac Inflow Disease (Leriche Syndrome): Characterized by severe atherosclerotic narrowing or occlusion of the infrarenal abdominal aorta and common iliac arteries. The classic Leriche triad comprises: (1) claudication of the buttocks, hips, and thighs, (2) absent or severely diminished femoral pulses, and (3) erectile dysfunction in men due to internal iliac / pudendal hypoperfusion.
2. Femoropopliteal Outflow Disease: The most frequent site of atherosclerotic stenosis in the general population. The superficial femoral artery (SFA) is uniquely vulnerable as it traverses the adductor hiatus (Hunter's canal), where mechanical tethering and repetitive muscular compression induce focal endothelial shear injury. Occlusion produces classic calf claudication.
3. Infrapopliteal (Tibial / Peroneal) Runoff Disease: Involves the anterior tibial, posterior tibial, and peroneal arteries below the knee. This pattern is disproportionately prevalent in patients with diabetes mellitus and end-stage renal disease (ESRD). Isolated infrapopliteal occlusions preserve femoral and popliteal pulses while eliminating pedal pulses, concentrating ischemic necrosis in the distal toes and heel.

---

Clinical Staging: Fontaine vs. Rutherford Classification

Two validated staging systems are universally employed to categorize the clinical severity of lower extremity arterial disease:

Chronic Limb-Threatening Ischemia (CLTI)

Historically termed "Critical Limb Ischemia (CLI)", contemporary consensus guidelines designate patients with Rutherford Category 4, 5, or 6 (Fontaine Stage III or IV) as having Chronic Limb-Threatening Ischemia (CLTI). CLTI is defined by the presence of peripheral arterial disease in combination with:

• Persistent, recurring ischemic rest pain requiring analgesia for > 2 weeks, OR
• A non-healing arterial ulceration, OR
• Localized or extensive pedal gangrene

CLTI indicates that resting microvascular blood flow is insufficient to sustain basal metabolic cellular viability. Without rapid vascular intervention, the 1-year major amputation rate is approximately 25%, and 1-year mortality approaches 20% to 25%.

---

Clinical Semiology of Lower Extremity Ischemia

+-------------------------------------------------------------------------------------------------+
|                   CLINICAL COMPARISON: EXERTIONAL CLAUDICATION VS. REST PAIN                     |
+-------------------------------------------------------------------------------------------------+
| CLINICAL FEATURE    | INTERMITTENT CLAUDICATION         | ISCHEMIC REST PAIN (CLTI)             |
+---------------------+-----------------------------------+---------------------------------------+
| Pathophysiology     | Flow adequate at rest; demand     | Flow fails basal resting metabolic    |
|                     | exceeds supply during exercise    | requirement; severe tissue hypoxia    |
+---------------------+-----------------------------------+---------------------------------------+
| Pain Location       | Muscular bellies (calf, thigh)    | Distal forefoot, metatarsal heads, toes|
+---------------------+-----------------------------------+---------------------------------------+
| Precipitating Event | Consistent walking distance/work  | Recumbency / sleep (loss of gravity)  |
+---------------------+-----------------------------------+---------------------------------------+
| Relieving Factor    | Standing still for 2 to 5 minutes | Dangling foot over bed / dependency   |
+---------------------+-----------------------------------+---------------------------------------+
| Objective Pressures | Ankle Pressure > 60-70 mmHg       | Ankle Pressure < 40-50 mmHg           |
|                     | Toe Pressure > 40-50 mmHg         | Toe Pressure < 30 mmHg; TcPO2 < 30    |
+---------------------+-----------------------------------+---------------------------------------+

1. Intermittent Claudication

Intermittent claudication is the earliest symptomatic manifestation of hemodynamically significant macrovascular stenosis:

• Pathophysiology: Under resting conditions, collateral arterial channels and distal arteriolar vasodilation maintain sufficient resting perfusion to keep skeletal muscle asymptomatic. During ambulation, contracting skeletal muscle oxygen consumption increases by 10- to 20-fold. Fixed upstream stenoses prevent the normal drop in vascular resistance and rise in arterial inflow. Anaerobic metabolism ensues, accumulating tissue lactic acid, potassium ions, adenosine, and substance P within muscular fascial compartments, stimulating chemosensitive Group III and IV nociceptors.
• Clinical Characteristics: The patient describes a reproducible, predictable aching, cramping, heaviness, or burning sensation localized to specific muscular groups (most commonly the gastrocnemius-soleus complex of the calf). The pain begins after walking a constant, predictable distance (claudication distance), worsens with continued ambulation or incline walking, and completely subsides within 2 to 5 minutes of standing motionless.
• Differential Diagnosis (Pseudoclaudication / Neurogenic Claudication): Lumbar spinal canal stenosis compresses the cauda equina, causing exertional buttock and leg pain. Unlike vascular claudication, neurogenic claudication is posture-dependent: it is exacerbated by spinal extension (standing upright or walking downhill) and relieved only by spinal flexion (sitting down, stooping forward, or leaning over a shopping cart [the "shopping cart sign"]). Relief requires 15 to 30 minutes of seated rest rather than 2 to 5 minutes of standing still.

2. Ischemic Rest Pain

Ischemic rest pain signifies severe, decompensated arterial insufficiency (Fontaine III / Rutherford 4):

• Mechanism: In severe PAD, resting ankle perfusion pressure plummets below 40 to 50 mmHg (or toe pressure below 30 mmHg), breaching the critical opening pressure of microvascular precapillary arterioles. When the patient lies supine in bed at night, two physiological events converge: (1) the loss of gravitational hydrostatic assistance (which adds approximately 0.77 mmHg per centimeter of distance below the heart in the standing position), and (2) the physiological nocturnal reduction in systemic mean arterial pressure and cardiac output. This causes microvascular capillary collapse in the distal foot.
• Symptom Profile: The patient experiences an unremitting, severe, burning or lancinating ache localized to the distal forefoot and toes (especially the metatarsal heads and digital tips). The pain characteristically awakens the patient from sleep after 1 to 2 hours of recumbency.
• The Classic Dependency Maneuver: To obtain relief, the patient instinctively sits on the edge of the bed and dangles the ischemic foot over the side, or gets out of bed to pace slowly, or sleeps upright in a recliner chair. Dangling the foot recruits gravity, increasing hydrostatic capillary perfusion pressure by roughly 40 to 60 mmHg, temporarily re-opening collapsed capillary beds and mitigating ischemic pain. Persistent dependent positioning, however, frequently causes marked dependent gravitational edema, which paradoxically increases interstitial tissue pressure and further compromises microvascular exchange.

3. Physical Examination Signs: Buerger's Test & Trophic Markers

• Buerger's Test (Elevation Pallor & Dependent Rubor):
  • Elevation Pallor: With the patient supine, the examiner elevates both lower limbs to a 45° to 60° angle for 60 seconds. In healthy limbs with normal perfusion pressure, the plantar skin remains pink. In an ischemic limb, the low arterial perfusion pressure cannot overcome gravitational hydrostatic resistance, causing rapid draining of blood from the dermal subpapillary plexus. The plantar skin becomes pale, cadaveric, and chalky-white within 25 to 30 seconds. The angle at which pallor develops is the Buerger angle of circulatory sufficiency; an angle < 20° indicates severe, limb-threatening ischemia.
  • Dependent Rubor ("Sunset Foot"): Following elevation, the patient quickly swings the legs over the examination table into a dependent position. In healthy limbs, normal pink color returns within 10 seconds. In severe ischemia, blood takes 20 to 30 seconds to reach the foot. Over the subsequent 1 to 2 minutes, the foot develops a deep, fiery, violaceous, cyanotic red discoloration termed dependent rubor. This is not indicative of healthy hyperperfusion; rather, prolonged chronic tissue hypoxia causes maximal paralysis and dilation of the precapillary arteriolar sphincters mediated by local adenosine and nitric oxide. When blood slowly pools in this paralyzed microvasculature, deoxygenation occurs rapidly, creating a dark cyanotic red hue that blanches poorly with pressure.
• Venous Filling Time: With the patient supine, the examiner elevates the leg to collapse the dorsal veins, then lowers the foot into dependency. In healthy vessels, the dorsal veins fill within 10 to 15 seconds. A venous refilling time > 20 to 30 seconds indicates severe arterial inflow reduction.
• Trophic Cutaneous Markers: Chronic nutritive hypoperfusion produces profound tissue atrophy:
  • Cutaneous Atrophy: The skin becomes cool, pale, thin, shiny, and parchment-like.
  • Phalangeal & Pretibial Madarosis: Permanent loss of hair over the dorsal toes, metatarsals, and anterior lower leg due to ischemic atrophy of hair follicle bulbs.
  • Onychodystrophy: Toenails become thickened, yellow, brittle, slow-growing, and transversely ridged.
  • Digital Subcutaneous Atrophy: The distal pulp of the toes shrinks, producing pinched, pointed, skeletal-appearing digits.

---

Morphology & Characteristics of Arterial Ulcers

Arterial ulcers exhibit distinct anatomic and morphological features that distinguish them from neuropathic and venous ulcers:

+-------------------------------------------------------------------------------------------------+
|                        MORPHOLOGICAL SIGNATURE OF AN ARTERIAL ULCER                             |
+-------------------------------------------------------------------------------------------------+
| • WOUND MARGINS:   "Punched-out", sharply circumscribed, regular borders; steep vertical edges |
| • WOUND BED:       Pale, dry, avascular, grey-yellow slough or hard, black, leathery ESCHAR     |
|                    Granulation tissue is completely absent or pale, stunted, and fibrotic       |
| • EXUDATE LEVEL:   Minimal to dry; zero exudate unless secondarily infected                     |
| • PERIWOUND:       Pale, cool, atrophic, hairless, parchment-like skin; no hemosiderin staining |
| • ANATOMICAL SITES:Distal tips of toes, interdigital web spaces, lateral malleolus, heel,       |
|                    dorsal foot, or over bony pressure points from footwear                      |
| • PAIN SEVERITY:   Intensely painful; exacerbated by leg elevation; partially relieved by      |
|                    dependent positioning                                                        |
| • PULSES:          Dorsalis pedis and posterior tibial pulses absent or severely diminished     |
+-------------------------------------------------------------------------------------------------+

Dry Gangrene Management: The Sterile Shield Principle

A dry, uninfected, stable black eschar on an ischemic toe or heel (dry gangrene) represents mummified tissue that acts as a sterile biological shield:

• The Non-Intervention Rule: In the outpatient wound clinic, a stable dry eschar must NEVER be sharp-debrided, aggressively unroofed, cross-hatched, or soaked in wet dressings prior to successful arterial revascularization.
• The Catastrophic Conversion to Wet Gangrene: Debriding an unvascularized ischemic eschar violates the protective barrier and introduces opportunistic pathogens into an avascular, necrotic tissue bed completely devoid of host defense mechanisms and blood flow. This instantly converts a stable, dry lesion into fulminant, limb- and life-threatening wet gangrene and ascending necrotizing phlegmon, forcing emergent major limb amputation.
• Management Protocol: Paint the dry eschar with an alcohol-based antiseptic or topical povidone-iodine (Betadine) to maintain sterility and desiccation, cover with dry sterile non-adherent gauze, protect from external pressure, and obtain immediate vascular surgical consultation for revascularization. Debridement is performed only AFTER pulsatile arterial inflow is restored or when moist demarcation / purulence indicates secondary bacterial liquefaction.

---

Evidence-Based Medical Management of PAD & CLTI

Comprehensive medical therapy serves two distinct goals: (1) systemic cardiovascular risk reduction to prevent myocardial infarction and stroke (MACE), and (2) limb salvage to prevent major amputation (MALE).

+-------------------------------------------------------------------------------------------------+
|                         EVIDENCE-BASED MEDICAL MANAGEMENT OF PAD                                |
+-------------------------------------------------------------------------------------------------+
| 1. ABSOLUTE SMOKING CESSATION                                                                   |
|    • Single most important lifestyle intervention; lowers amputation and cardiovascular risk      |
|    • Pharmacotherapy: Varenicline, Bupropion, and dual Nicotine Replacement Therapy (NRT)       |
+-------------------------------------------------------------------------------------------------+
| 2. HIGH-INTENSITY STATIN THERAPY                                                                |
|    • Atorvastatin 80 mg or Rosuvastatin 20-40 mg daily (Target LDL-C < 55 mg/dL)                |
|    • Pleiotropic plaque stabilization, reduces systemic MACE and limb-specific MALE             |
+-------------------------------------------------------------------------------------------------+
| 3. ANTITHROMBOTIC THERAPY: MONOTHERAPY VS. DUAL PATHWAY INHIBITION                              |
|    • Antiplatelet Monotherapy: Aspirin 81 mg daily OR Clopidogrel 75 mg daily (CAPRIE trial)     |
|    • COMPASS Trial Breakthrough Regimen (Dual Pathway Inhibition):                              |
|      -> Low-dose Rivaroxaban 2.5 mg BID + Aspirin 100 mg daily                                   |
|      -> Reduces MACE by 24% and reduces Major Adverse Limb Events (MALE/Amputation) by 46%     |
+-------------------------------------------------------------------------------------------------+
| 4. PHOSPHODIESTERASE-3 INHIBITION (Cilostazol)                                                  |
|    • Cilostazol 100 mg BID: Increases intracellular cAMP -> Vasodilation & antiplatelet action |
|    • Increases pain-free and maximal walking distance by 40% to 50% in claudication             |
|    • ABSOLUTE CONTRAINDICATION: Congestive Heart Failure (CHF) of ANY severity (Black-Box!)     |
+-------------------------------------------------------------------------------------------------+
| 5. BLOOD PRESSURE & GLYCEMIC TARGETS                                                            |
|    • BP Target < 130/80 mmHg (ACE inhibitors / ARBs preferred; HOPE trial)                      |
|    • Glycemic Target: HbA1c < 7.0-8.0%                                                          |
+-------------------------------------------------------------------------------------------------+

1. Smoking Cessation

Cigarette smoking is the single most potent modifiable risk factor for the incidence, progression, and amputation risk of PAD. Inhaled nicotine and combustion byproducts induce intense peripheral vasoconstriction, downregulate endothelial nitric oxide, accelerate LDL oxidation, elevate circulating fibrinogen, and activate platelets. Smoking cessation is associated with lower amputation rates, better bypass graft patency, and lower cardiovascular mortality. Behavioral support combined with first-line pharmacotherapy (varenicline, bupropion, or dual nicotine replacement therapy) must be initiated aggressively.

2. High-Intensity Statin Therapy

Guidelines from the AHA/ACC and SVS mandate high-intensity statin therapy (e.g., atorvastatin 80 mg or rosuvastatin 20 to 40 mg daily) for all patients with PAD, irrespective of baseline serum cholesterol. Statins exert powerful pleiotropic effects: they stabilize atherosclerotic plaques by thickening the fibrous cap, inhibit vascular cell inflammation, decrease platelet reactivity, and upregulate eNOS. High-intensity statins reduce all-cause mortality, stroke, myocardial infarction, and limb loss.

3. Antithrombotic Regimens & The COMPASS Trial

• Antiplatelet Monotherapy: Aspirin (81 to 100 mg daily) or clopidogrel (75 mg daily) is recommended for symptomatic PAD. The landmark CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) demonstrated that clopidogrel monotherapy provided a modest but statistically significant relative risk reduction in ischemic events compared to aspirin monotherapy in the PAD subgroup.
• Dual Pathway Inhibition (The COMPASS Trial): The randomized, double-blind COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) evaluated 27,395 patients with stable atherosclerotic vascular disease, including a large cohort with lower extremity PAD. The trial compared three regimens: (1) rivaroxaban 2.5 mg twice daily PLUS aspirin 100 mg once daily, (2) rivaroxaban 5 mg twice daily alone, and (3) aspirin 100 mg once daily alone.
  • Findings: The combination of very low-dose rivaroxaban (2.5 mg BID) plus aspirin (100 mg daily) achieved a 24% relative reduction in the primary composite endpoint of MACE (cardiovascular death, stroke, or MI).
  • Limb-Specific Outcomes: In the PAD cohort, dual pathway inhibition resulted in a dramatic 46% relative reduction in Major Adverse Limb Events (MALE), including a dramatic reduction in major lower limb amputations, compared to aspirin alone. Although major gastrointestinal bleeding was increased, fatal and intracranial bleeding rates were not significantly different. Dual pathway inhibition is now strongly endorsed as standard-of-care medical management for ambulatory PAD patients at high risk for limb events who lack high bleeding risks.

4. Cilostazol & The Absolute Heart Failure Contraindication

• Mechanism of Action: Cilostazol (Pletal) is a selective inhibitor of phosphodiesterase type 3 (PDE-3). By preventing the breakdown of cyclic adenosine monophosphate (cAMP), it increases intracellular cAMP concentrations in vascular smooth muscle and platelets. Elevated cAMP activates Protein Kinase A (PKA), leading to: (1) smooth muscle relaxation and arterial vasodilation, (2) inhibition of platelet aggregation and activation, (3) inhibition of vascular smooth muscle cell proliferation, and (4) favorable alterations in plasma lipoproteins (reducing triglycerides and increasing HDL).
• Clinical Efficacy: In multiple prospective, randomized, placebo-controlled trials, cilostazol (100 mg orally twice daily taken 30 minutes before or 2 hours after meals) significantly improved pain-free walking distance by 40% to 50% and maximal treadmill walking distance in patients with moderate-to-severe intermittent claudication. It does not treat rest pain or promote ulcer healing in CLTI.
• ABSOLUTE BLACK-BOX CONTRAINDICATION (Congestive Heart Failure): Cilostazol carries an FDA Black-Box Warning strictly contraindicating its use in patients with congestive heart failure (CHF) of ANY severity or ejection fraction (including NYHA Class I through IV, and both HFpEF and HFrEF). Other PDE-3 inhibitors with inotropic properties (such as oral milrinone and vesnarinone) were evaluated in large CHF clinical trials (e.g., the PROMISE trial), where they produced an intolerable, statistically significant increase in ventricular tachyarrhythmias and sudden cardiovascular mortality. Because cilostazol shares this exact biochemical mechanism, its use in CHF is lethal and universally contraindicated.
• Pentoxifylline: A methylxanthine derivative that alters red and white blood cell deformability to decrease blood viscosity (rheologic agent). It demonstrates marginal, inconsistent clinical efficacy in claudication trials and is relegated to a distant second-line option for patients intolerant of cilostazol.

---

Indications for Urgent Vascular Revascularization & The BEST-CLI Trial

Wound healing cannot occur when tissue perfusion falls below metabolic thresholds. Timely referral to vascular surgery for revascularization is life- and limb-saving:

+-------------------------------------------------------------------------------------------------+
|                        INDICATIONS FOR URGENT VASCULAR SURGICAL CONSULT                         |
+-------------------------------------------------------------------------------------------------+
| 1. CHRONIC LIMB-THREATENING ISCHEMIA (CLTI)                                                     |
|    • Ischemic rest pain persisting > 2 weeks (Fontaine III / Rutherford 4)                      |
|    • Non-healing arterial ulceration persisting > 2 weeks despite local care (Rutherford 5)     |
|    • Localized or spreading digital/heel gangrene (Rutherford 5/6)                              |
+-------------------------------------------------------------------------------------------------+
| 2. ACUTE LIMB ISCHEMIA (ALI) - THE "SIX Ps"                                                    |
|    • Pain, Pallor, Pulselessness, Poikilothermia, Paresthesias, Paralysis                        |
|    • Rutherford ALI Category IIa (Marginally threatened) or IIb (Immediately threatened)        |
|    • Requires emergent surgical thromboembolectomy, catheter-directed thrombolysis, or bypass   |
|      within 4 to 6 hours to prevent irreversible neuromuscular ischemic necrosis               |
+-------------------------------------------------------------------------------------------------+
| 3. INFECTION SUPERIMPOSED ON AN ISCHEMIC EXTREMITY                                              |
|    • Wet gangrene, ascending necrotizing soft tissue infection, or deep phlegmon                |
|    • Requires emergent surgical drainage/debridement paired with immediate vascular inflow     |
+-------------------------------------------------------------------------------------------------+

Revascularization Modalities: Endovascular vs. Surgical Bypass (The BEST-CLI Trial)

• Endovascular Therapy (Percutaneous Transluminal Angioplasty [PTA], Drug-Coated Balloons [DCB], Stenting, Atherectomy): Less invasive, preferred in frail elderly patients with high surgical perioperative morbidity or those lacking a suitable autologous vein conduit. Excellent for focal aortoiliac or superficial femoral artery lesions.
• Open Surgical Bypass (Autologous Vein vs. Prosthetic Conduit): The landmark randomized BEST-CLI trial (Best Endovascular versus Best Surgical Therapy in Patients with Chronic Limb-Threatening Ischemia, 2022) evaluated whether surgical bypass or endovascular therapy yielded superior outcomes in CLTI patients:
  • Cohort 1 (Patients with an Adequate Great Saphenous Vein Conduit): In patients who possessed a suitable single-segment autologous great saphenous vein (GSV), surgical bypass resulted in a statistically significant 32% reduction in the composite of major adverse limb events (MALE) or death compared with endovascular treatment, driven mainly by fewer major reinterventions; above-ankle amputations were numerically, but not clearly significantly, lower.
  • Cohort 2 (Patients Lacking an Adequate Vein Conduit): In patients who lacked an autologous GSV and required prosthetic or alternative grafts, outcomes between open surgery and endovascular therapy were comparable, supporting endovascular-first interventions in this subset.